Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
The following section summarizes insights on Ocular Therapeutix Inc's Depreciation & Amortization Margin:
We've identified the following companies as similar to Ocular Therapeutix Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
| Name | Ticker | Depreciation & Amortization Margin |
|---|---|---|
| Evoke Pharma Inc | NASDAQCM:EVOK | 0.0% |
| Esperion Therapeutics Inc | NASDAQGM:ESPR | 0.0% |
| Corcept Therapeutics Incorporated | NASDAQCM:CORT | 0.1% |
| Tarsus Pharmaceuticals Inc | NASDAQGS:TARS | 0.7% |
| Vyne Therapeutics Inc | NASDAQCM:VYNE | 0.8% |
| Evolus Inc | NASDAQGM:EOLS | 2.0% |
| Harmony Biosciences Holdings | NASDAQGM:HRMY | 3.4% |
| Healthcare | SECTOR:HLTH.US | 5.8% |
| Ocular Therapeutix Inc | NASDAQGM:OCUL | 5.9% |
| Harrow Health Inc | NASDAQGM:HROW | 6.5% |
| Omeros Corporation | NASDAQGM:OMER | NA |
| 4Front Ventures Corp | OTCPK:FFNT.F | 6.7% |
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Depreciation & Amortization Margin in the efficiency category include:
Depreciation and amortization as a percent of revenue.
The depreciation & amortization margin measures a company’s depreciation & amortization as a percentage of the revenue. The formula to calculate depreciation & amortization margin and an example calculation for Ocular Therapeutix’s trailing twelve months is outlined below:
Depreciation & Amortization Margin = Depreciation & Amortization / Total Revenue
5.9% = 3.786 M / 63.723 M
The tables below summarizes Ocular Therapeutix’s performance over the last five years:
| Fiscal Year | Depreciation & Amortization | Revenue | Margin |
|---|---|---|---|
| 2020-12-31 | 2.773 M | 17.403 M | 15.9% |
| 2021-12-31 | 2.421 M | 43.522 M | 5.6% |
| 2022-12-31 | 2.109 M | 51.494 M | 4.1% |
| 2023-12-31 | 2.983 M | 58.443 M | 5.1% |
| 2024-12-31 | 3.786 M | 63.723 M | 5.9% |
The tables below summarizes Ocular Therapeutix’s performance over the last four quarters:
| Quarter Ending | Depreciation & Amortization | Revenue | Margin |
|---|---|---|---|
| 2024-03-31 | 920 T | 14.774 M | 6.2% |
| 2024-06-30 | 956 T | 16.441 M | 5.8% |
| 2024-09-30 | 959 T | 15.425 M | 6.2% |
| 2024-12-31 | 951 T | 17.082 M | 5.6% |
You can read more about Depreciation & Amortization here.
The chart above depicts the distribution of Depreciation & Amortization Margin for companies operating in the Healthcare Sector in the Developed economic region. Over 2,000 companies were considered in this analysis, and 1,927 had meaningful values. The average Depreciation & Amortization Margin of companies in the Sector is 29.1% with a standard deviation of 93.3%. Please note that Sector and Industry values may differ from other sources, as no adjustments have been made.
Ocular Therapeutix Inc's Depreciation & Amortization Margin of 5.9% ranks in the 54.6% percentile for the Sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,007 |
| Included Constituents | 1,927 |
| Min | -0.1% |
| Max | 929.6% |
| Median | 5.0% |
| Mean | 29.1% |
| Standard Deviation | 93.3% |
You can find companies with similar Depreciation & Amortization Margin using this stock screener.